Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote
After publishing: 3 URLs changed3 changes
- wkms.orgseen 29 Sept, 05:38URL changed
now resolves towww.wkms.org/npr-news/2026-09-23/fda-advisory-panel-recommends-a-first-multi-cancer-blood-test
- wutc.orgseen 29 Sept, 05:40URL changed
now resolves towww.wutc.org/2026-09-23/fda-advisory-panel-recommends-a-first-multi-cancer-blood-test
- kedm.orgseen 3 Oct, 15:26URL changed
now resolves towww.kedm.org/npr-news/2026-09-23/fda-advisory-panel-recommends-a-first-multi-cancer-blood-test
What it is about
Who published it, and when
2 reports left out of the cascade - too little in common with the story to place
How it spread - 4 original reports, 3 reprints
Wed, 23 September 2026
3 reports- NPR News10:00
The company Grail says its Galleri blood test can detect up to 50 forms of cancer. An independent panel of experts will decide if the test should be recommended for FDA approval.
3 reprints
- kedm.org23 Sept, 10:00their copy
- wkms.org23 Sept, 10:00their copy
- wutc.org23 Sept, 10:00their copy
- yahoo.com23:08first to report
A U.S. Food and Drug Administration advisory panel voted in favor of recommending that the agency approve a blood test for multiple cancers on Wednesday. The assay, called the Galleri test, is design...
- klkntv.com23:10
WASHINGTON (AP) — Federal health advisers on Wednesday endorsed a blood test designed to spot signs of various cancers in apparently healthy people while warning that it’s far from clear how well the technology works. Grail Inc.’s Galleri test doesn’t diagnose cancer but instead, with a single blood draw, looks for a signal that someone may have one of a...
Thu, 24 September 2026
1 report- South China Morning Post10:05
Efforts to detect multiple cancers through a single blood draw are gathering momentum after US regulators endorsed the technology for the first time, although experts say wider adoption in Hong Kong still faces challenges as doctors remain cautious about its clinical value. In a landmark decision for the emerging field of multi-cancer early detection (MCED) blood tests, a US Food and Drug Administration (FDA) panel on Thursday voted in favour of US company Grail’s “Galleri test”, recommending...